Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

NATCOPHARM's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 4.09800
forwardPE 21.80994
debtToEquity 3.01200
earningsGrowth -0.23500
revenueGrowth -0.00600
grossMargins 0.82408
operatingMargins 0.38650
trailingEps 85.94000
forwardEps 38.14545

NATCOPHARM's current ratio 4.098, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, NATCOPHARM can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
NATCOPHARM's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
NATCOPHARM's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
Positive gross and operating margins for NATCO Pharma Limited highlight the company's profitability. These metrics reflect NATCO Pharma Limited's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
NATCO Pharma Limited's forward EPS being lower than its trailing EPS suggests the company is expected to see reduced profitability in the current financial year compared to the previous one. This signals a potential decline in earnings, raising concerns about future financial performance.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

The price of NATCOPHARM has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


6 NATCOPHARM shares were sold in recent transactions, with market price at 1017.8999938964844.2 separate transactions to buy NATCOPHARM were completed, while market price hovered around 851.625.NATCOPHARM has seen more sells than buys at current price levels, which could point to a potential price drop. If this selling trend persists, it may indicate that investors are expecting further declines in the stock's value.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


NATCOPHARM has received no definitive buy or sell ratings from analysts, presenting a mixed outlook for the stock. This uncertainty could leave investors hesitant, prompting them to consider other market indicators before making any investment decisions.